SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

KALA

KALA BIO, Inc.
NASDAQHealth Care

Latest close: 0.19 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 10, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 9, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 28, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year249
SEC filings on record62134 flagged findings
Reported transactions (Form 4)80since Jun 22, 2023 · and 11 other holdings
Corporate events (8-K)30since Oct 2, 2025

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-06-12share offering or dilution eventrecentOpen filing ↗
    “…to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; ● the dates on which the…”
    +1 more passage from the same document
    • “…upon exercise of the warrants; ● the dates on which the right to exercise the warrants will commence and expire or, if the…”
  • 2026-06-12reverse splitrecentOpen filing ↗
    “…commercial deployment with external customers. There can be no assurance that these efforts will identify commercially actionable…”
    +1 more passage from the same document
    • “…our biologics portfolio and our Researgency business, which may include licensing. 2 Reverse Stock Split On May 7, 2026, we filed…”
  • 2026-05-15share offering or dilution eventrecentOpen filing ↗
    “…BIO, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (In thousands, except share and per share amounts)…”
    +1 more passage from the same document
    • “…Rule. ATM Facility On January 8, 2026, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with Wainwright…”
  • 2026-05-15listing compliance noticerecentOpen filing ↗
    “…In addition, on January 20, 2026, we received a letter from the Staff indicating that, based upon the closing bid price of the…”
    +1 more passage from the same document
    • “…bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum…”
  • 2026-05-15capital return (buybacks/dividends)recentOpen filing ↗
    “…or grant any stock options, restricted stock units or restricted stock awards, during the period covered by this Quarterly…”
  • 2026-05-15merger or acquisition eventrecentOpen filing ↗
    “…in a low single digit percentage range on net sales of licensed products that are covered by a valid claim of a licensed patent. A…”
    +1 more passage from the same document
    • “…of $ 2,500 in cash and $ 2,354 in shares of the Company’s Common Stock (representing an aggregate of 2,100 shares of the…”
  • 2026-05-15reverse splitrecentOpen filing ↗
    “…to deploy as a dedicated, on-premises AI infrastructure solution for biotechnology and pharmaceutical companies. We believe this…”
    +1 more passage from the same document
    • “…for biotechnology and pharmaceutical companies. We believe this dual-track strategy preserves and creates optionality with…”
  • 2026-05-07share offering or dilution eventrecentOpen filing ↗
    “…to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; ● the dates on which the…”
    +1 more passage from the same document
    • “…upon exercise of the warrants; ● the dates on which the right to exercise the warrants will commence and expire or, if the…”

7 older entries not shown

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Listing notice in force

The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of Aug 28, 2026).

Deadline: May 9, 2026 · passed

  • market value of listed securities · Nasdaq, rule 5550(b)(2) · notice of Nov 10, 2025 · pending · deadline May 9, 2026 (text and rule agree) · first period expired; a second 180-day period may exist that is not on record
  • minimum bid price · Nasdaq, rule 5550(a)(2) · notice of Jan 20, 2026 · extension granted · deadline Jul 19, 2026 (text and rule agree) · first period expired; a second 180-day period may exist that is not on record

The other times

Of the 30 issuers that received this notice 1 to 2 years ago, within the following 365 days 16 regained compliance, 23 did a reverse split and 1 filed a Form 25 (delisting). An issuer can be in more than one group.

Measured on our own SEC documents: the cohort is the issuers whose notices we read, not the whole market. Historical distribution, not a prediction.

Open the 8-K at the SEC

Reverse splits in 5 years

2 reverse splits in 5 years (1:50 on Oct 21, 2022, 1:50 on May 11, 2026) · 1:2500 cumulative

The other times: of 247 securities that repeated a reverse split in 5 years, a year later the median was worth 0.10× the price on the day of the split; 189 lost more than half and 21 rose (243 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 621)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 24, 26DEF 14A ↗Shareholder meeting and votes
  • Sep 11, 26PRE 14A ↗Shareholder meeting and votes
  • Sep 10, 268-K ↗Current report · Entered a material agreement
  • Sep 9, 268-K ↗Current report · Board nominations · Other events
  • Aug 28, 268-K ↗Current report · Listing notice (8-K 3.01)
  • Aug 19, 2610-Q ↗Quarterly report
  • Aug 14, 26NT 10-Q ↗Late filing notice
  • Jul 23, 268-K ↗Current report · Other events
  • Jul 22, 26424B5 ↗Securities offering
  • Jul 2, 26SCHEDULE 13D/A ↗Stake with intent to influence · Lazar David E. · 3.9% · event on May 20, 26 · amendment
  • Jun 12, 26S-3/A ↗Securities offering · amendment
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Baker Bros. Advisors LP · 0.0% · event on Mar 31, 26 · amendment
  • May 15, 2610-Q ↗Quarterly report
  • May 7, 26S-3 ↗Securities offering
  • May 7, 268-K ↗Current report · Change in shareholder rights · Bylaws or fiscal year change · Other events
  • Apr 15, 2610-K ↗Annual report
  • Mar 31, 26NT 10-K ↗Late filing notice
  • Notice of proposed sale · 3 Form 144 filingsshow all 3hide
  • Mar 4, 268-K ↗Current report · Entered a material agreement
  • Feb 20, 268-K ↗Current report · A senior executive left or was appointed
  • Feb 17, 26424B3 ↗Securities offering
  • Feb 17, 26SCHEDULE 13G/A ↗Passive stake · Baker Bros. Advisors LP · 10.0% · event on Dec 31, 25 · amendment
  • Feb 13, 26CORRESP ↗Correspondence with the SEC

621 filings on record, the oldest from Oct 20, 15.

Listing the 25 most recent filings of the 621 on record.

8-Ks, explained

Stress12Structure47Governance26
  • Sep 10, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Aug 28, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Mar 4, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Feb 20, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Feb 5, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Feb 2, 26StructureEntered a material agreement+6 more in the same filing8-K 1.01 ↗
  • Jan 23, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jan 8, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 6, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Dec 29, 25GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Dec 16, 25GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Dec 5, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗

5 older filings not shown · The record reaches back to Aug 11, 17.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Nov 12, 25StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Oct 20, 25StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Oct 2, 25StressRestructuring plan with committed costs+2 more in the same filing8-K/A 2.05 ↗
  • Oct 1, 25StressA debt obligation was accelerated8-K 2.04 ↗
  • Sep 29, 25StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Dec 9, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jul 8, 22StressRestructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗
  • May 27, 22StressListing notice (8-K 3.01)8-K 3.01 ↗

The full record holds 12 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Baker Bros. Advisors LP10.0%Sep 30, 25SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • David E. Lazar5.2%Jan 30, 26SCHEDULE 13D ↗
  • SR One Capital Fund II Aggregator, LP4.6%Oct 14, 25SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Lazar David E.3.9%May 20, 26SCHEDULE 13D/A ↗

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • OXFORD FINANCE LLC16.5%Nov 25, 25SCHEDULE 13G ↗
  • Cormorant Asset Management, LP10.0%Dec 31, 24SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • LifeSci Capital LLC7.9%Dec 30, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Perceptive Advisors LLC7.7%Sep 4, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Point72 Asset Management, L.P.6.7%Sep 4, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
show 2 more holdershide
  • ADAR1 Capital Management, LLC4.9%Dec 31, 24SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Baker Bros. Advisors LP0.0%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 23, 25Sell$125KMark T Iwicki↗
  • Oct 23, 25Sell$793Mary ReumuthCHIEF FINANCIAL OFFICER↗
  • Oct 22, 25Sell$39KRomulus K BrazzellSEE REMARKS↗
  • Oct 22, 25Sell$40KTodd Bazemore↗
  • Oct 22, 25Sell$27KMary ReumuthCHIEF FINANCIAL OFFICER↗
  • Oct 22, 25Sell$17KDarius KharabiCHIEF BUSINESS OFFICER↗
  • Oct 1, 25Sell$70KBAKER BROS. ADVISORS LP↗
  • Oct 1, 25Sell$641KBAKER BROS. ADVISORS LP↗
  • Sep 30, 25Sell$34KBAKER BROS. ADVISORS LP↗
  • Sep 30, 25Sell$312KBAKER BROS. ADVISORS LP↗
  • Jun 24, 25Sell$53KMark T Iwicki↗
  • Jun 24, 25Sell$21KRomulus K BrazzellSEE REMARKS↗

There are 17 more transactions in this stretch.

Stock compensation, tax and giftsshow the 11 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jun 15, 25Compensationamount n/aANDREW I KOVEN↗
  • Jun 15, 25Compensationamount n/aC. Daniel Myers↗
  • Jun 15, 25Compensationamount n/aGREGORY D PERRY↗
  • Jun 15, 25Compensationamount n/aMarjan Farid↗
  • Jun 15, 25Compensationamount n/aMark T Iwicki↗
  • Jun 15, 25Compensationamount n/aHoward B Rosen↗
  • Jan 6, 25Compensationamount n/aMary ReumuthCHIEF FINANCIAL OFFICER↗
  • Jan 6, 25Compensationamount n/aMark T IwickiCHIEF EXECUTIVE OFFICER↗
  • Jan 6, 25Compensationamount n/aRomulus K BrazzellSEE REMARKS↗
  • Jan 6, 25Compensationamount n/aTodd BazemoreSEE REMARKS↗
  • Jan 6, 25Compensationamount n/aDarius KharabiCHIEF BUSINESS OFFICER↗

The full record holds 115 transactions and goes back to Feb 15, 22.

Its sector and its market

KALA BIO, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From KALA BIO, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow KALA BIO, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
621 documents on file, from Oct 20, 2015 to Sep 24, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.